You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR2 gene fusion or FGFR2 gene mutation or amplification

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma Trial in Worldwide (derazantinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular and Cholangiocarcinoma
  • Phoenix, Arizona
  • +40 more
Mar 7, 2022

Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

Not yet recruiting
  • Advanced Cholangiocarcinoma
  • +2 more
  • (no location specified)
Feb 3, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Refractory Solid Tumors Trial in Seoul (pazopanib)

Completed
  • Refractory Solid Tumors
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Cholangiocarcinoma
  • Liver Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)

Recruiting
  • Solid Tumor
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

Refractory Solid Tumors Trial in Seoul (sunitinib)

Completed
  • Refractory Solid Tumors
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Advanced Intrahepatic Cholangiocarcinoma Trial (Pemigatinib)

Not yet recruiting
  • Advanced Intrahepatic Cholangiocarcinoma
  • (no location specified)
Sep 30, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

An Intervention to Increase Genetic Testing in Families Who May

Recruiting
  • BRCA1 Mutation
  • +21 more
  • Intervention Arm At-risk Relative/ARR Contacts
  • +5 more
  • Basking Ridge, New Jersey
  • +7 more
Nov 22, 2022

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

ARID1A Gene Mutation, ATM Gene Mutation, ATR Gene Mutation Trial in United States (Olaparib)

Recruiting
  • ARID1A Gene Mutation
  • +15 more
  • Scottsdale, Arizona
  • +4 more
Dec 13, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Leber Congenital Amaurosis Trial in Shanghai (HG004)

Recruiting
  • Leber Congenital Amaurosis
  • HG004
  • Shanghai, Shanghai, China
    Xinhua Hospital affiliated with Shanghai Jiao Tong UniversitySch
Oct 12, 2023

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Cholangiocarcinoma,Adult Trial (3D185)

Not yet recruiting
  • Cholangiocarcinoma,Adult
  • (no location specified)
Sep 2, 2021